Richard Weinshilboum

Richard Weinshilboum has integrated pharmacometabolomics with pharmacogenomics to predict individual cancer patient responses to chemotherapy, identifying metabolic biomarkers that explain inter-patient variability in drug efficacy and toxicity. His foundational work on thiopurine pharmacogenetics established the paradigm of using metabolic phenotyping to guide cancer drug dosing. His metabolomics-informed precision oncology approaches have been implemented clinically at Mayo Clinic for personalizing cancer treatment selection.